These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 38323767)
1. [Metabolic steatotic liver disease: the move towards an inclusive definition]. Zampaglione L; Marello N; Petignat PA Rev Med Suisse; 2024 Feb; 20(860):311-315. PubMed ID: 38323767 [TBL] [Abstract][Full Text] [Related]
2. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease. Loomba R; Wong VW Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279 [TBL] [Abstract][Full Text] [Related]
3. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity. Kim GA; Moon JH; Kim W Clin Mol Hepatol; 2023 Oct; 29(4):831-843. PubMed ID: 37634892 [TBL] [Abstract][Full Text] [Related]
5. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A; Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202 [TBL] [Abstract][Full Text] [Related]
6. Waiting for the changes after the adoption of steatotic liver disease. Yoon EL; Jun DW Clin Mol Hepatol; 2023 Oct; 29(4):844-850. PubMed ID: 37670441 [TBL] [Abstract][Full Text] [Related]
7. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Castro Narro GE; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN; J Hepatol; 2023 Dec; 79(6):1542-1556. PubMed ID: 37364790 [TBL] [Abstract][Full Text] [Related]
8. [Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases]. Chen L; Jiang LN; Zhao JM Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):805-809. PubMed ID: 37723061 [TBL] [Abstract][Full Text] [Related]
9. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Castro Narro GE; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN; Hepatology; 2023 Dec; 78(6):1966-1986. PubMed ID: 37363821 [TBL] [Abstract][Full Text] [Related]
10. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Narro GEC; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN; Ann Hepatol; 2024; 29(1):101133. PubMed ID: 37364816 [TBL] [Abstract][Full Text] [Related]
11. Association between Alcohol Consumption and Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Alcohol Flushing Response in Men: The Korea National Health and Nutrition Examination Survey 2019-2021. Kang DE; Oh SN Nutrients; 2023 Sep; 15(18):. PubMed ID: 37764685 [TBL] [Abstract][Full Text] [Related]
12. [Discussion from metabolism to fatty liver disease: rethinking the origin of disease and the endpoint of new drugs or metabolic dysfunction-associated steatotic liver disease]. Xue F; Wei L Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):785-788. PubMed ID: 37723057 [TBL] [Abstract][Full Text] [Related]
14. Embracing Change: From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease Under the Steatotic Liver Disease Umbrella. Noureddin M; Wei L; Castera L; Tsochatzis EA Clin Gastroenterol Hepatol; 2024 Jan; 22(1):9-11. PubMed ID: 37848118 [No Abstract] [Full Text] [Related]
15. Exploring the landscape of steatotic liver disease in the general US population. Ciardullo S; Carbone M; Invernizzi P; Perseghin G Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856 [TBL] [Abstract][Full Text] [Related]
16. Applying proteomics in metabolic dysfunction-associated steatotic liver disease: From mechanism to biomarkers. Zhang X; Li X; Xiong X Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102230. PubMed ID: 37931846 [TBL] [Abstract][Full Text] [Related]